E-viri
PDF
Recenzirano
Odprti dostop
-
The oncologist (Dayton, Ohio), July 2020, Letnik: 25, Številka: S1Journal Article
Zanubrutinib, obinutuzumab, and venetoclax (BOVen), given on a treatment schedule driven by minimal residual disease milestones, is a promising approach to previously untreated chronic lymphocytic leukemia, according to new findings from an investigator‐initiated phase II study.
